Diseases (NIAID) and the U.S. Army Medical Research Institute for
Infectious Diseases (USAMRIID) to explore cethromycin's activity against
high-priority bioterror agents for its use as a broad spectrum
countermeasure. Submit proposals to the Department of Defense and the
Department of Health and Human Services to fund the advanced development
of cethromycin in combating bioterror agents such as anthrax, tularemia,
plague and Burkholderia pseudomallei;
* Initiate enrollment by the end of the summer in Phase I/II
dose-escalating study to assess the safety, tolerability, and
preliminary efficacy of ALS-357 topically administered to patients with
cutaneous metastatic melanoma;
* Present cethromycin clinical data at ICAAC in the Fall.
Financial Guidance for 2008
Advanced Life Sciences expects its 2008 cash requirements excluding milestone payments that become due upon NDA filing to fall in the range of $16 million and $17 million. The first quarter cash use of $5.7 million reflects continued NDA submission costs that will curtail substantially in the coming quarters. Accordingly, we expect our quarterly cash use to decrease as we move forward with our operations. The cash used will be applied toward remaining cethromycin NDA submission activities, manufacturing costs, medical communication investments, ALS-357 clinical costs, and general operating expenses. We believe that this cash balance will be sufficient to allow us to progress into a commercial partnership which will support the ongoing funding needs of the Company.
Conference Call Details
Advanced Life Sciences will host a conference call and live webcast at 10:00 a.m. Eastern Time on Wednesday, May 7, 2008 to discuss the Company's financial results for the first quarter.
The conference call will be webcast simultaneously o
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved